B. Brenner, M. Cooper, D. De-zeeuw, W. Keane, W. Mitch et al., Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy, New England Journal of Medicine, vol.345, issue.12, pp.861-870, 2001.
DOI : 10.1056/NEJMoa011161

F. Holtkamp, D. De-zeeuw, P. De-graeff, G. Laverman, T. Berl et al., Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials, European Heart Journal, vol.32, issue.12, pp.1493-1502, 2011.
DOI : 10.1093/eurheartj/ehr017

H. Parving, H. Lehnert, J. Brochner-mortensen, R. Gomis, S. Andersen et al., The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with Type 2 Diabetes, New England Journal of Medicine, vol.345, issue.12, pp.870-878, 2001.
DOI : 10.1056/NEJMoa011489

J. Luo, S. Brunelli, D. Jensen, and Y. A. , Association between Serum Potassium and Outcomes in Patients with Reduced Kidney Function, Clinical Journal of the American Society of Nephrology, vol.11, issue.1, pp.90-100, 2016.
DOI : 10.2215/CJN.01730215

URL : http://cjasn.asnjournals.org/content/11/1/90.full.pdf

B. Palmer, Managing Hyperkalemia Caused by Inhibitors of the Renin???Angiotensin???Aldosterone System, New England Journal of Medicine, vol.351, issue.6, pp.585-92, 2004.
DOI : 10.1056/NEJMra035279

P. Rossignol, F. Zannad, and B. Pitt, Time to retrieve the best benefits from renin angiotensin aldosterone system (RAAS) inhibition in heart failure patients with reduced ejection fraction: Lessons from randomized controlled trials and registries, International Journal of Cardiology, vol.177, issue.3, pp.731-734, 2014.
DOI : 10.1016/j.ijcard.2014.11.004

P. Rossignol, M. Legrand, M. Kosiborod, S. Hollenberg, W. Peacock et al., Emergency management of severe hyperkalemia: Guideline for best practice and opportunities for the future, Pharmacological Research, vol.113, pp.585-91, 2016.
DOI : 10.1016/j.phrs.2016.09.039

F. Zannad, P. Rossignol, W. Stough, M. Epstein, A. Garcia-mde et al., New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approval, International Journal of Cardiology, vol.216, pp.46-51, 2016.
DOI : 10.1016/j.ijcard.2016.04.127

N. Jain, S. Kotla, B. Little, R. Weideman, E. Brilakis et al., Predictors of Hyperkalemia and Death in Patients With Cardiac and Renal Disease, The American Journal of Cardiology, vol.109, issue.10, pp.1510-1513, 2012.
DOI : 10.1016/j.amjcard.2012.01.367

P. Rossignol, D. Dobre, J. Mm, K. Swedberg, H. Krum et al., Incidence, Determinants, and Prognostic Significance of Hyperkalemia and Worsening Renal Function in Patients With Heart Failure Receiving the Mineralocorticoid Receptor Antagonist Eplerenone or Placebo in Addition to Optimal Medical Therapy: Results From the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF), Circulation: Heart Failure, vol.7, issue.1, pp.51-59, 2014.
DOI : 10.1161/CIRCHEARTFAILURE.113.000792

Y. Miao, D. Dobre, H. Heerspink, B. Brenner, M. Cooper et al., Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial, Diabetologia, vol.16, issue.Suppl 1, pp.44-50, 2011.
DOI : 10.1007/s00125-010-1922-6

C. Bowling, B. Pitt, M. Ahmed, I. Aban, P. Sanders et al., Hypokalemia and Outcomes in Patients With Chronic Heart Failure and Chronic Kidney Disease: Findings From Propensity-Matched Studies, Circulation: Heart Failure, vol.3, issue.2, pp.253-60, 2010.
DOI : 10.1161/CIRCHEARTFAILURE.109.899526

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2909749

O. Vardeny, D. Wu, A. Desai, P. Rossignol, F. Zannad et al., Influence of Baseline and Worsening Renal Function on Efficacy of Spironolactone in Patients With Severe Heart Failure, Journal of the American College of Cardiology, vol.60, issue.20, pp.2082-2091, 2012.
DOI : 10.1016/j.jacc.2012.07.048

S. Korgaonkar, A. Tilea, B. Gillespie, M. Kiser, G. Eisele et al., Serum Potassium and Outcomes in CKD: Insights from the RRI-CKD Cohort Study, Clinical Journal of the American Society of Nephrology, vol.5, issue.5, pp.762-771, 2010.
DOI : 10.2215/CJN.05850809

J. Hayes, K. Kalantar-zadeh, J. Lu, S. Turban, J. Anderson et al., Association of Hypo- and Hyperkalemia with Disease Progression and Mortality in Males with Chronic Kidney Disease: The Role of Race, Nephron Clinical Practice, vol.120, issue.1, pp.8-16, 2012.
DOI : 10.1159/000329511

H. Wang, C. Hung, D. Hwang, M. Kuo, Y. Chiu et al., Hypokalemia, Its Contributing Factors and Renal Outcomes in Patients with Chronic Kidney Disease, PLoS ONE, vol.19, issue.7, p.67140, 2013.
DOI : 10.1371/journal.pone.0067140.s004

G. Nakhoul, H. Huang, S. Arrigain, S. Jolly, J. Schold et al., Serum Potassium, End-Stage Renal Disease and Mortality in Chronic Kidney Disease, American Journal of Nephrology, vol.41, issue.6, pp.456-63, 2015.
DOI : 10.1159/000437151

M. Glick, Methodology for potassium analysis. Potassium, its biologic significance, p.9, 1983.

G. Lum and S. Gambino, A Comparison of Serum versus Heparinized Plasma for Routine Chemistry Tests, American Journal of Clinical Pathology, vol.61, issue.1, pp.108-121, 1974.
DOI : 10.1093/ajcp/61.1.108

O. Moranne, M. Froissart, J. Rossert, C. Gauci, J. Boffa et al., Timing of Onset of CKD-Related Metabolic Complications, Journal of the American Society of Nephrology, vol.20, issue.1, pp.164-71, 2009.
DOI : 10.1681/ASN.2008020159

URL : https://hal.archives-ouvertes.fr/inserm-00555033

M. Noordzij, K. Leffondre, K. Van-stralen, C. Zoccali, F. Dekker et al., When do we need competing risks methods for survival analysis in nephrology?, Nephrology Dialysis Transplantation, vol.28, issue.11, pp.2670-2677, 2013.
DOI : 10.1093/ndt/gft355

URL : https://academic.oup.com/ndt/article-pdf/28/11/2670/6905007/gft355.pdf

K. Group and . Kdigo, Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease, Kidney Int, issue.3, pp.1-150, 2012.

M. Krogager, C. Torp-pedersen, R. Mortensen, L. Kober, G. Gislason et al., Short-term mortality risk of serum potassium levels in hypertension: a retrospective analysis of nationwide registry data, European Heart Journal, vol.38, issue.2, pp.104-116, 2017.
DOI : 10.1093/eurheartj/ehw129

B. Pitt and P. Rossignol, Potassium lowering agents: Recommendations for physician and patient education, treatment reappraisal, and serial monitoring of potassium in patients with chronic hyperkalemia, Pharmacological Research, vol.118, pp.2-4, 2017.
DOI : 10.1016/j.phrs.2016.07.032

B. Pitt and G. Bakris, New Potassium Binders for the Treatment of Hyperkalemia, Hypertension, vol.66, issue.4, pp.731-739, 2015.
DOI : 10.1161/HYPERTENSIONAHA.115.04889

B. Pitt and P. Rossignol, The association between serum potassium and mortality in patients with hypertension, Eur Heart J, vol.38, issue.2, pp.113-118, 2017.

M. Raebel, D. Mcclure, K. Chan, S. Simon, A. Feldstein et al., Laboratory Evaluation of Potassium and Creatinine Among Ambulatory Patients Prescribed Spironolactone: Are We Monitoring for Hyperkalemia?, Annals of Pharmacotherapy, vol.16, issue.2, pp.193-200, 2007.
DOI : 10.1002/pds.1217

L. Cooper, B. Hammill, E. Peterson, B. Pitt, M. Maciejewski et al., Consistency of Laboratory Monitoring During Initiation of Mineralocorticoid Receptor Antagonist Therapy in Patients With Heart Failure, JAMA, vol.314, issue.18, pp.1973-1978, 2015.
DOI : 10.1001/jama.2015.11904